Vaxcyte Shares Decline as Capital Research Global Investors Reduces Stake

Institutional investor sells nearly 4 million shares of the biotech company

Mar. 13, 2026 at 8:20am

Got story updates? Submit your updates here. ›

Capital Research Global Investors, a major institutional investor, has decreased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 82.3% in the third quarter, according to a recent SEC filing. The firm now owns 842,978 shares of the company's stock, down from over 4.7 million shares previously.

Why it matters

Vaxcyte is a clinical-stage biotech company focused on developing a new generation of preventive vaccines, including its lead candidate VAX-24, a 24-valent pneumococcal conjugate vaccine. The significant reduction in Capital Research Global Investors' position could signal a shift in sentiment around the company's prospects.

The details

According to the SEC filing, Capital Research Global Investors sold 3,928,808 shares of Vaxcyte during the third quarter, reducing its stake by 82.3%. The firm now owns 842,978 shares, or 0.64% of the company's outstanding stock, worth approximately $30.4 million as of the most recent filing.

  • Capital Research Global Investors decreased its stake in Vaxcyte during the third quarter of 2026.

The players

Capital Research Global Investors

A major institutional investor that has significantly reduced its stake in Vaxcyte, Inc.

Vaxcyte, Inc.

A clinical-stage biotechnology company focused on developing a new generation of preventive vaccines, including its lead candidate VAX-24.

Got photos? Submit your photos here. ›

The takeaway

The substantial reduction in Capital Research Global Investors' position in Vaxcyte could signal a shift in sentiment around the company's prospects, potentially impacting the stock price and investor confidence in the biotech's vaccine development pipeline.